FG
TEVA icon

Fairman Group’s Teva Pharmaceuticals TEVA Stock Holding History

Fairman Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.98K Hold
206
– – 0.01% 183
2026
Q1 		$6.21K Hold
206
– – 0.01% 178
2025
Q4 		$6.43K Hold
206
– – 0.01% 179
2025
Q3 		$4.16K Buy
+206
New +$3.62K ﹤0.01% 205

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.63B AUM 45.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
KHLMVGHM
Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet Tel Aviv, Israel $2.44B AUM 24.95% 1-Year Est. Return
YDMI
Y.D. More Investments Ramat Gan, Israel $3.21B AUM 117.29% 1-Year Est. Return

Fairman Group's TEVA Position: Q2 2026 in Review

Fairman Group held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 206 shares worth $6.98K. The position accounts for 0.01% of the portfolio, ranked #183.

Fairman Group first reported a position in TEVA in Q3 2025 and has held it in 4 quarters since. 331 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Fairman Group held 206 shares of Teva Pharmaceuticals worth $6.98K as of Q2 2026.
  • Fairman Group left its Teva Pharmaceuticals share count unchanged in Q2 2026.
  • Teva Pharmaceuticals made up 0.01% of Fairman Group's portfolio in Q2 2026, its #183 holding.
  • Fairman Group first reported a position in Teva Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 331 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Fairman Group's 13F filing for Q2 2026, filed 4 Aug 2026.